Good day, ladies and gentlemen, and welcome to the Emergent BioSolutions third quarter 2013 financial results conference call. My name is Brittney, and I'll be the operator for today. (Operator Instructions) At this time, I would now like to turn the presentation over to your host for today, Mr. Bob Burrows. Please proceed, sir.

Thank you, Brittney. Good afternoon, ladies and gentlemen. Thank you for joining us today as we discuss Emergent BioSolutions' financial results for the third quarter and first nine months of 2013. As is customary, our call today is open to all participants. In addition, the call is being recorded and is copyrighted by Emergent BioSolutions. Participating on the call this afternoon with prepared comments will be Dan Abdun-Nabi, our President and CEO; and Bob Kramer, our Chief Financial Officer. Following the prepared comments we will conduct a question-and-answer session. Before we begin I am compelled to remind everyone that during the call management may make projections and other forward-looking statements regarding future events and the company's prospects of future performance. These forward-looking statements reflect Emergent's current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve substantial risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements. You are encouraged to review Emergent's filings with the SEC on Forms 10-K, 10-Q and 8-K for more information on the risks and uncertainties that could cause actual results to differ. For the benefit of those who may be listening to the replay this call is held and recorded on November 7, 2013. Since then Emergent may have made announcements relating to topics discussed during today's call. So again, please reference our most recent press releases and SEC filings. Emergent BioSolutions assumes no obligation to update the information in today's press release or as presented on this call, except as may be required by applicable laws or regulations. Today's press release may be found on our website at www.emergentbiosolutions.com under investors/news. And with that introduction, I would now like to turn the call over to Dan Abdun-Nabi, Emergent BioSolutions' President and CEO. Dan?

Thank you, Bob. Good afternoon, everyone, and thank you for joining our call today. During my prepared comments I will discuss our Q3 and year-to-date financial results, our 2013 financial guidance and our recent operational performance. Total revenue for the third quarter was $89 million, which is above the $70 million to $80 million range that we provided on our call in August. Total revenue for the first nine months was $215 million. Net income for the third quarter was $13.5 million or $0.37 per share and year-to-date net income was just under $16 million or $0.44 per share. Bob Kramer, will provide more details on our financial performance in a moment. As announced in today's press release, we are revising upward our 2013 forecast to the upper-end of our previous guidance. Specifically, we anticipate total revenue of $300 million to $310 million, including product revenue of $250 million to $255 million and contracts and grants revenue of $50 million to $55 million. We also anticipate net income of between $25 million to $30 million. Now, I'll summarize our recent operational performance starting with Biodefense. Through Q3 2013 we have delivered approximately 15 million doses of BioThrax, under our existing supply contract, which caused a delivery of the total of 44.75 million to the SNS. Total revenues realized today under this contract is approximately $400 million, at a total contract value of $1.25 billion. Deliveries are on schedule and we currently anticipate that deliveries under this contract will continue through Q3 2016. In July we received approval from the Paul-Ehrlich-Institut to market BioThrax in Germany with a three-dose primary schedule over six months with triennial boosters thereafter. This approval makes BioThrax the only vaccine approved in Germany for the prevention of anthrax disease. With this approval we are now initiating…

Thanks, Dan. Good afternoon, everyone. Let me start by adding some additional color to Dan's earlier comment on our 2013 revenue and net income guidance. And then I'll turn our performance for the quarter and for the first nine months of the year. Based on our results to date and supported by the visibility we have through yearend, we are revising upwards our revenue net income guidance for the year. Specifically, we're narrowing guidance to the upper-end to the previous ranges and are now forecasting total revenues of between $300 million and $310 million and net income of $25 million to $30 million. With respect to the revenue mix, we're now forecasting product sales of between $250 million and $255 million comprised of BioThrax and RSDL sales, and contracts and grants revenue of between $50 million and $55 million. I'll now turn to our financial performance, starting with the quarter. Our core business turned in solid financial results evidenced by total revenues of $89 million, which include product sale of $76 million and contracts and grants of $13 million. Drilling a bit deeper, product sales for the period included $69 million in BioThrax sales and $7 million of RSDL sales. Total revenue for the quarter was 34% better than 3Q of the prior year and reflect increased shipments of BioThrax as well as the initial sales of RSDL. Gross margin for the quarter was 74%. Importantly, the third quarter gross margin reflects the impact of RSDL sales. Going forward, we anticipate the consolidated gross margin will continue in historical range of 78%, inclusive of the lower margin RSDL sales. For 3Q 2013, our gross R&D cost was slightly higher than prior year, adding increase by $1.5 million as we invest in our development programs to enable partnering of certain assets.…

(Operator Instructions) And your first question comes from the line of Eric Schmidt. Eric Schmidt - Cowen & Company: Maybe just starting with you, Bob, the RSDL number looked quite a bit bigger than I think we had expected at least, probably others as well, and probably above your guidance. Is this a run rate going forward that we should model off of?

No. I think, Eric, as we commented a couple of months ago, historically under the prior ownership the annual sales of RSDL were in the $18 million to $20 million range. I think our initial experience with RSDL is better than what we expected, or again it is a IDIQ contract. So the sales will be a little bit lumpy and we continue to expect that. We can improve upon the history of what the prior owner did with the business and I would stick with the ranges that we gave before. Eric Schmidt - Cowen & Company: And maybe you said this, I could have missed it, the taxes in Q3 were below your guidance for what reason?

Well, we continue to benefit from the orphan drug treatment of certain R&D expenses and tax credits. Eric Schmidt - Cowen & Company: And that'll only last as long as TRU-016 continues?

It will be significantly impacted by the otlertuzumab with the TRU-016 expenses, yes. Eric Schmidt - Cowen & Company: And then maybe just on TRU-016, maybe Dan, can talk about whether the partners have already seen the data in the ASH abstracts and that's going to be presented at the meetings? And whether that's in any way accelerated the pace of discussions.

We're very excited about the data that's coming out on otlertuzumab. And as we've indicated there's strong interest and we are engaged in discussions with partners. So under the confidentiality we have shared information and I think that data is supporting the negotiations and the confidence that we have moving this to a successful completion. Eric Schmidt - Cowen & Company: And last question, Dan, I think you had mentioned that you were hopeful for additional European approvals of BioThrax through the mutual recognition procedures. What countries in particular might approve it under that procedure, or where are you targeting your efforts?

We're staking that effort. We haven't finalized the sequential processing of that just yet. But it is primarily in some of the major countries there and we have prioritized it based on input from the countries that have expressed the interest as well as where we see some particularly attractive market opportunities. As well these approvals I think will support NATO interest in the product as well, so I think it has the double effect, not only country interest, but also potentially NATO interest. So from our standpoint that will be a program that we will have, starting this year and continuing next year. So our expectation is that you will see our own series of approvals being announced over the course of next year.

And your next question comes from the line of Cory Kasimov.

This is Whitney on for Cory today. And I sort of hopped on late, so I apologize if this has already been answered, but relative to Building 55, I think you guys said that you're still on track to submit the sBLA by next year. So I was just wondering in terms of the FDA request whether you sort of ended up looking at a greater number of proteins or if maybe you're confident that the analytical data that you guys have will support the data you initially submitted

So in terms of growth, we had submitted our data package addressing the protein profile for the product and we are looking to sit down with the FDA before the yearend and just go through that data package and reach agreement on the protein profile that will be demonstrated in the consistency lot showing comparability between 12 and 55. So we're optimistic candidly because as I said in the prior call, it's really data-driven and the FDA is very science-oriented and data-oriented, so I think when we go through that package that we've submitted, we'll successfully target the important proteins that will demonstrate comparability and consistency with manufacturing and that will unable us to complete the comparability package and get that in front of the agency core that targeted 2015 approval.

And your next question comes from the line of James Molloy.

A couple quick questions on the products, I am willing to ask a couple of omab. On the RSDL sales, I mean it was already asked, but higher than expected. It was higher than I expected, as well. Anyway, the key drivers here besides just sort of the normal lumpiness in the contract and then you had spoken before about new formulations and ways to really boost sales. Any developments on new formulation potential for RSDL?

As you might expect when we originally disclose the target customers for RSDL, its DoD and NATO. There is a supply arrangement under both organizations and the predominant customer in this case was DoD as Rob explained. There were also some NATO purchases, but to a much lesser extent. And as Bob indicated, this is an IDIQ indefinite delivery, indefinite quantity contract, so those sales will be lumpy based on need by the Department of Defense. So the other part new question was, remind me now.

On the last call you talked about the opportunity to perhaps do new formulations, put in on something to wash down a tank or something like that. Any developments?

We are still evaluating on how best to address the new market opportunities that are presented by this product, and so we have not initiated any actions to start line extensions on it as of yet.

And then quickly, any pull-forward from the fourth quarter on BioThrax? It was certainly a good quarter here, and I know that, again, BioThrax can be lumpy given the batch processing and delivery. Should we expect any quarter-to-quarter softness next quarter because some orders came in here?

I think we've now got the nine months figure out there and we've given you the full year guidance and there will be a range there depending on final deliveries and release of product to be delivered, so there could be some variability, but I think it's a pretty tight range.

Then lastly on omag, the data that came out, the Phase 2 data, it looked pretty strong. I mean, it's Phase 2, but for these refractory CLLs, I mean, Campath filed on three Phase 2s. I know you've discussed what you need in a Phase 3 before you could file, but is this something similar to a Campath where someone could do another, smaller or a little bit larger Phase 2 and come into a Phase 4 later and then file on this thing? I mean could you compare sort of the data you put out versus a Campath?

I think it is exciting data. I think it supports the potential use of the product in combination setting. And as we said previously this product plays well within a number of potential product, so I think it's got a wide bandwidth potentially going forward, but in terms of the actual clinical program to what might be required, I'm going to ask Scott Stromatt, our CMO to really address that question for you. Scott, are you online?

Campath was approved a few years ago and the field has moved towards PFS data and the latest trial, obinutuzumab was approved based on over 400 and so patients, so we expect that we'd have to have a similar number of patients and we will discuss this with the agency at our inter-Phase 2 meeting next year.

So that's where you're thinking moving the new guidance? You're not going to be able to do a similar kind of smaller studies and get this thing through? You'll need a multi-hundred study or your partner will.

There are no further questions. I will now turn the call back over to Mr. Burrows for further comments.

Thank you, Brittany. Ladies and gentlemen, thank you for your participation. Please note that today's call has been recorded and the replay will be available beginning later today. Alternatively there is available webcast of today's call, and archive version of which will be available later this evening, accessible to through the company website. Thank you again, and we look forward to speaking to all of you in future. Good luck.

Ladies and gentlemen, that concludes the presentation for today's conference. You may now all disconnect and have a wonderful day.